Steroid / thiopurine refractory UC

  • Steroid-refractory disease includes relapse within 3 months of steroid-induced remission

Steroid or thiopurine refractory disease

  • Confirm disease activity (biomarkers incl. calprotectin).

  • Exclude infection due to C. difficile.

  • Consider endoscopy to assess activity, and exclude CMV, and cancer.

Assess disease extent and activity

  • Continue thiopurine for a total of 3 months to determine if responsive disease

  • Treat left-sided and extensive mild colitis

  • Escalate from failed therapies in the context of disease activity

Treat appropriately

ECCO statement 11K (UC 2017)

Patients with moderate colitis refractory to thiopurines should be treated with anti-TNF [EL1], preferably combined with thiopurines, at least for infliximab [EL2], or vedolizumab [EL2]. In case of treatment failure, a different anti-TNF [EL4] or vedolizumab [EL2] should be considered, and colectomy recommended if further medical therapy does not achieve a clear clinical benefit [EL5]

ECCO statement 12I (UC 2017)

Anti-TNF or vedolizumab may be used as first-line biological therapy. Vedolizumab is effective in patients failing anti-TNF [EL2]. In patients responding to vedolizumab, maintenance therapy with vedolizumab is appropriate [EL2]

Further information

  • Anti-TNF + thiopurines provide steroid free remission in 40% at 4 months, and 25% at 1 year

  • It is unclear whether thiopurines should be continued if previously thiopurine-refractory, in which case methotrexate may have a role

  • Limited data for tacrolimus. Vedolizumab is a valid therapy

Anti-TNF or Vedolizumab

  • Continue anti-TNF ± thiopurine

  • Consider stepping down to thiopurine maintenance therapy in those previously thiopurine-naïve with sustained deep remission

Continue therapy

Optimise therapy

  • Consider semi-elective colectomy (no treatment achieves steroid free remission in the majority)

Colectomy

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.